S&P 500   3,278.95 (+1.09%)
DOW   28,778.62 (+0.85%)
QQQ   221.33 (+1.48%)
AAPL   316.58 (+2.47%)
FB   217.81 (+1.37%)
MSFT   165.31 (+1.87%)
GOOGL   1,451.74 (+1.40%)
AMZN   1,849.71 (+1.17%)
CGC   22.80 (+5.75%)
NVDA   246.59 (+2.66%)
BABA   209.17 (+1.80%)
MU   56.44 (+1.86%)
GE   11.66 (+1.92%)
TSLA   562.82 (+0.86%)
AMD   50.18 (+1.87%)
T   38.71 (+1.20%)
F   8.96 (+0.67%)
NFLX   349.15 (+1.83%)
BAC   33.41 (+1.70%)
DIS   138.33 (+1.79%)
GILD   64.53 (+1.10%)
S&P 500   3,278.95 (+1.09%)
DOW   28,778.62 (+0.85%)
QQQ   221.33 (+1.48%)
AAPL   316.58 (+2.47%)
FB   217.81 (+1.37%)
MSFT   165.31 (+1.87%)
GOOGL   1,451.74 (+1.40%)
AMZN   1,849.71 (+1.17%)
CGC   22.80 (+5.75%)
NVDA   246.59 (+2.66%)
BABA   209.17 (+1.80%)
MU   56.44 (+1.86%)
GE   11.66 (+1.92%)
TSLA   562.82 (+0.86%)
AMD   50.18 (+1.87%)
T   38.71 (+1.20%)
F   8.96 (+0.67%)
NFLX   349.15 (+1.83%)
BAC   33.41 (+1.70%)
DIS   138.33 (+1.79%)
GILD   64.53 (+1.10%)
S&P 500   3,278.95 (+1.09%)
DOW   28,778.62 (+0.85%)
QQQ   221.33 (+1.48%)
AAPL   316.58 (+2.47%)
FB   217.81 (+1.37%)
MSFT   165.31 (+1.87%)
GOOGL   1,451.74 (+1.40%)
AMZN   1,849.71 (+1.17%)
CGC   22.80 (+5.75%)
NVDA   246.59 (+2.66%)
BABA   209.17 (+1.80%)
MU   56.44 (+1.86%)
GE   11.66 (+1.92%)
TSLA   562.82 (+0.86%)
AMD   50.18 (+1.87%)
T   38.71 (+1.20%)
F   8.96 (+0.67%)
NFLX   349.15 (+1.83%)
BAC   33.41 (+1.70%)
DIS   138.33 (+1.79%)
GILD   64.53 (+1.10%)
S&P 500   3,278.95 (+1.09%)
DOW   28,778.62 (+0.85%)
QQQ   221.33 (+1.48%)
AAPL   316.58 (+2.47%)
FB   217.81 (+1.37%)
MSFT   165.31 (+1.87%)
GOOGL   1,451.74 (+1.40%)
AMZN   1,849.71 (+1.17%)
CGC   22.80 (+5.75%)
NVDA   246.59 (+2.66%)
BABA   209.17 (+1.80%)
MU   56.44 (+1.86%)
GE   11.66 (+1.92%)
TSLA   562.82 (+0.86%)
AMD   50.18 (+1.87%)
T   38.71 (+1.20%)
F   8.96 (+0.67%)
NFLX   349.15 (+1.83%)
BAC   33.41 (+1.70%)
DIS   138.33 (+1.79%)
GILD   64.53 (+1.10%)
Log in

NASDAQ:GNFT - GENFIT S A/ADR Stock Price, Forecast & News

$17.95
-0.14 (-0.77 %)
(As of 01/28/2020 01:02 PM ET)
Today's Range
$17.86
Now: $17.95
$17.96
50-Day Range
$15.45
MA: $19.11
$20.76
52-Week Range
$13.21
Now: $17.95
$26.25
Volume1,005 shs
Average Volume57,518 shs
Market Capitalization$679.05 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, and autoimmune or fibrotic diseases affecting primarily the liver and gastro-enterology. The company's lead products include Elafibranor, which is in pivotal Phase 3 clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as in Phase 2 study in patients with primary biliary cholangitis; and Nitazoxanide that is in Phase 2 proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis. It is also developing in-vitro diagnostic test for the identification of patients with NASH; and TGFTX1 preclinical program for treating psoriasis or respiratory conditions, such as neutrophilic asthma, chronic obstructive pulmonary disease (COPD), and the asthma-COPD overlap syndrome. Genfit SA was founded in 1999 and is headquartered in Loos, France.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GNFT
CUSIPN/A
CIKN/A
Phone33-3-20-16-40-00

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$8.85 million

Profitability

Miscellaneous

Employees148
Market Cap$679.05 million
Next Earnings DateN/A
OptionableNot Optionable

Receive GNFT News and Ratings via Email

Sign-up to receive the latest news and ratings for GNFT and its competitors with MarketBeat's FREE daily newsletter.


GENFIT S A/ADR (NASDAQ:GNFT) Frequently Asked Questions

What is GENFIT S A/ADR's stock symbol?

GENFIT S A/ADR trades on the NASDAQ under the ticker symbol "GNFT."

What price target have analysts set for GNFT?

7 brokerages have issued 1-year price objectives for GENFIT S A/ADR's stock. Their forecasts range from $25.47 to $58.00. On average, they anticipate GENFIT S A/ADR's stock price to reach $47.89 in the next year. This suggests a possible upside of 166.8% from the stock's current price. View Analyst Price Targets for GENFIT S A/ADR.

What is the consensus analysts' recommendation for GENFIT S A/ADR?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GENFIT S A/ADR in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for GENFIT S A/ADR.

Has GENFIT S A/ADR been receiving favorable news coverage?

Media coverage about GNFT stock has trended somewhat positive on Tuesday, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. GENFIT S A/ADR earned a news sentiment score of 0.8 on InfoTrie's scale. They also gave news stories about the company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an impact on the stock's share price in the next few days. View News Stories for GENFIT S A/ADR.

Who are some of GENFIT S A/ADR's key competitors?

What other stocks do shareholders of GENFIT S A/ADR own?

Who are GENFIT S A/ADR's key executives?

GENFIT S A/ADR's management team includes the folowing people:
  • Mr. Jean-François Mouney, Co-Founder, CEO & Chairman (Age 64)
  • Ms. Nathalie Huitorel, Exec. VP, Chief Financial & Admin. Officer (Age 58)
  • Dr. Dean W. Hum, Chief Operating Officer (Age 57)
  • Prof. Bart Staels, Co-Founder & Pres of the Scientific Advisory Board (Age 56)
  • Mr. Laurent Lannoo, Corp. Sec. & Director of Legal Affairs (Age 49)

When did GENFIT S A/ADR IPO?

(GNFT) raised $132 million in an initial public offering (IPO) on Wednesday, March 27th 2019. The company issued 5,000,000 shares at $26.33 per share. SVB Leerink and Barclays acted as the underwriters for the IPO and Bryan, Garnier, Natixis, Roth Capital Partners and H.C. Wainwright & Co. were co-managers.

How do I buy shares of GENFIT S A/ADR?

Shares of GNFT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is GENFIT S A/ADR's stock price today?

One share of GNFT stock can currently be purchased for approximately $17.95.

How big of a company is GENFIT S A/ADR?

GENFIT S A/ADR has a market capitalization of $679.05 million and generates $8.85 million in revenue each year. GENFIT S A/ADR employs 148 workers across the globe.View Additional Information About GENFIT S A/ADR.

What is GENFIT S A/ADR's official website?

The official website for GENFIT S A/ADR is http://www.genfit.com/.

How can I contact GENFIT S A/ADR?

GENFIT S A/ADR's mailing address is PARC EURASANTE 885 AVENUE EUGENE AVINEE, LOOS I0, 59120. The company can be reached via phone at 33-3-20-16-40-00 or via email at [email protected]


MarketBeat Community Rating for GENFIT S A/ADR (NASDAQ GNFT)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  31 (Vote Outperform)
Underperform Votes:  25 (Vote Underperform)
Total Votes:  56
MarketBeat's community ratings are surveys of what our community members think about GENFIT S A/ADR and other stocks. Vote "Outperform" if you believe GNFT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNFT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/28/2020 by MarketBeat.com Staff

Featured Article: Closed-End Mutual Funds

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel